The FDA and Pfizer only counted cases after the THIRD mRNA dose. But of the 375 Sars-Cov-2 infections in the trial, 365 occurred before the third dose. Only 10 occurred after the third dose. The efficacy rate is based on only 3% of all of the infections in the trial.